p27 KIP 1 (CDKN1B) (NM_004064) Human Recombinant Protein

CAT#: TP710154

Recombinant protein of human cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B), full length, with C-terminal DDK tag, expressed in sf9, 20ug

Product Images

Specifications

Product Data

• Species: Human
• Expression Host: Sf9
• Expression cDNA Clone or AA Sequence:
  Protein Sequence

  A DNA sequence from TrueORF clone, RC201661, encoding human full-length CDKN1B
• Tag: C-DDK
• Predicted MW: 22.1 kDa
• Concentration: >0.05 µg/µL as determined by microplate BCA method
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Buffer: 50 mM Tris-HCl, 100 mM glycine, pH 8.0, 10% glycerol
• Note: For testing in cell culture applications, please filter before use. Note that you may experience some loss of protein during the filtration process.
• Storage: Store at -80°C.
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.

Reference Data

• RefSeq: NP_004055
• Locus ID: 1027
• UniProt ID: P46527, Q6I9V6
• Cytogenetics: 12p13.1
• Refseq Size: 2422
• Refseq ORF: 594
• Synonyms: CDKN4; KIP1; MEN1B; MEN4; P27KIP1
• Summary: This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014]
• Protein Families: Druggable Genome
• Protein Pathways: Cell cycle, Chronic myeloid leukemia, ErbB signaling pathway, Pathways in cancer, Prostate cancer, Small cell lung cancer